Sector Gamma AS Has $2.15 Million Stake in Organon & Co. $OGN

Sector Gamma AS trimmed its position in shares of Organon & Co. (NYSE:OGN) by 44.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 300,000 shares of the company’s stock after selling 243,711 shares during the period. Sector Gamma AS’s holdings in Organon & Co. were worth $2,151,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in OGN. Vanguard Group Inc. lifted its holdings in shares of Organon & Co. by 11.3% during the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after buying an additional 3,650,860 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Organon & Co. by 136.1% in the 2nd quarter. AQR Capital Management LLC now owns 3,254,884 shares of the company’s stock valued at $31,507,000 after acquiring an additional 1,876,264 shares in the last quarter. UBS Group AG raised its stake in shares of Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after acquiring an additional 1,527,492 shares in the last quarter. Private Management Group Inc. raised its stake in shares of Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after acquiring an additional 1,204,979 shares in the last quarter. Finally, Balyasny Asset Management L.P. raised its stake in shares of Organon & Co. by 102.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock valued at $23,925,000 after acquiring an additional 1,131,941 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Stock Up 0.7%

Shares of OGN stock opened at $13.48 on Friday. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.42 and a current ratio of 1.97. The stock’s 50 day simple moving average is $11.47 and its 200 day simple moving average is $8.86. The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of 14.49, a PEG ratio of 1.24 and a beta of 1.55. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.49.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing the consensus estimate of $0.83 by ($0.12). The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.02 earnings per share. As a group, research analysts predict that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Monday, May 11th were given a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, May 11th. Organon & Co.’s payout ratio is currently 8.60%.

Analyst Ratings Changes

A number of research analysts recently weighed in on OGN shares. Barclays raised their price objective on Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research note on Tuesday, February 24th. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and raised their price objective for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. BNP Paribas Exane reissued a “neutral” rating and issued a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Weiss Ratings raised Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. Finally, Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $11.40.

Insider Buying and Selling

In other Organon & Co. news, SVP Lynette Holzbaur purchased 26,448 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were bought at an average cost of $13.35 per share, with a total value of $353,080.80. Following the transaction, the senior vice president directly owned 52,851 shares in the company, valued at approximately $705,560.85. This represents a 100.17% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.62% of the stock is currently owned by corporate insiders.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.